In:
Future Oncology, Future Medicine Ltd, Vol. 17, No. 11 ( 2021-04), p. 1295-1310
Abstract:
Lay abstract This work examined quality of life (QoL) among patients with relapsed/refractory diffuse large B-cell lymphoma with two to five prior therapies who received single-agent selinexor in the SADAL clinical trial. Analysis of patient-reported Functional Assessment of Cancer Therapy – Lymphoma and EuroQoL five-dimensions five-levels data showed that patients who had objective clinical response to selinexor maintained their QoL over the course of treatment. Grade ≥3 adverse events and serious adverse events were not associated with clinically meaningful negative QoL impacts. Clinical trial registration: NCT02227251 ( ClinicalTrials.gov )
Type of Medium:
Online Resource
ISSN:
1479-6694
,
1744-8301
DOI:
10.2217/fon-2020-0946
Language:
English
Publisher:
Future Medicine Ltd
Publication Date:
2021
Permalink